Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgrastim for acute-on-chronic liver failure
2015-002212-32Phase 2Completed
- Sponsor
- Leipzig University
- Start
- Oct 2015
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of filgrastim in acute-on-chronic liver failure (ACLF) and Cirrhosis (2 arms), sponsored by Leipzig University. Primary endpoint: Transplant-free survival at 90 days. Started Oct 2015; status: completed.
02
Drugs
filgrastim
03
Conditions
acute-on-chronic liver failure (ACLF)Cirrhosis
Beyond the preview
Go deeper on 2015-002212-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002212-32.